166 related articles for article (PubMed ID: 34854250)
21. Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma.
Rhee YY; Lee TH; Song YS; Wen X; Kim H; Jheon S; Lee CT; Kim J; Cho NY; Chung JH; Kang GH
Virchows Arch; 2015 Jun; 466(6):675-83. PubMed ID: 25772390
[TBL] [Abstract][Full Text] [Related]
22. Identification of prognostic signature of non-small cell lung cancer based on TCGA methylation data.
Wang Y; Wang Y; Wang Y; Zhang Y
Sci Rep; 2020 May; 10(1):8575. PubMed ID: 32444802
[TBL] [Abstract][Full Text] [Related]
23. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
24. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
25. USP4 expression independently predicts favorable survival in lung adenocarcinoma.
Zhong M; Jiang Q; Jin R
IUBMB Life; 2018 Jul; 70(7):670-677. PubMed ID: 29667299
[TBL] [Abstract][Full Text] [Related]
26. Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma.
Shen S; Wang G; Shi Q; Zhang R; Zhao Y; Wei Y; Chen F; Christiani DC
Clin Epigenetics; 2017; 9():88. PubMed ID: 28852427
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation biomarkers for the occurrence of lung adenocarcinoma from TCGA data mining.
Zhu XF; Zhu BS; Wu FM; Hu HB
J Cell Physiol; 2018 Oct; 233(10):6777-6784. PubMed ID: 29667778
[TBL] [Abstract][Full Text] [Related]
29. CANT1 serves as a potential prognostic factor for lung adenocarcinoma and promotes cell proliferation and invasion in vitro.
Yao Q; Yu Y; Wang Z; Zhang M; Ma J; Wu Y; Zheng Q; Li J
BMC Cancer; 2022 Jan; 22(1):117. PubMed ID: 35090419
[TBL] [Abstract][Full Text] [Related]
30. CpG methylation signature predicts prognosis in breast cancer.
Du T; Liu B; Wang Z; Wan X; Wu Y
Breast Cancer Res Treat; 2019 Dec; 178(3):565-572. PubMed ID: 31520283
[TBL] [Abstract][Full Text] [Related]
31. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
Chen D; Luo L; Liang C
PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
[TBL] [Abstract][Full Text] [Related]
32. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of novel DNA methylation markers for early diagnosis of lung adenocarcinoma.
Li M; Zhang C; Zhou L; Li S; Cao YJ; Wang L; Xiang R; Shi Y; Piao Y
Mol Oncol; 2020 Nov; 14(11):2744-2758. PubMed ID: 32688456
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
[TBL] [Abstract][Full Text] [Related]
35. A novel 14-gene signature for overall survival in lung adenocarcinoma based on the Bayesian hierarchical Cox proportional hazards model.
Sun N; Chu J; Hu W; Chen X; Yi N; Shen Y
Sci Rep; 2022 Jan; 12(1):27. PubMed ID: 34996932
[TBL] [Abstract][Full Text] [Related]
36. DNA methylation markers of surfactant proteins in lung cancer.
Lin Z; Thomas NJ; Bibikova M; Seifart C; Wang Y; Guo X; Wang G; Vollmer E; Goldmann T; Garcia EW; Zhou L; Fan JB; Floros J
Int J Oncol; 2007 Jul; 31(1):181-91. PubMed ID: 17549420
[TBL] [Abstract][Full Text] [Related]
37. Creation of a Prognostic Risk Prediction Model for Lung Adenocarcinoma Based on Gene Expression, Methylation, and Clinical Characteristics.
Ke H; Wu Y; Wang R; Wu X
Med Sci Monit; 2020 Oct; 26():e925833. PubMed ID: 33021972
[TBL] [Abstract][Full Text] [Related]
38. Multi-platform analysis of methylation-regulated genes in human lung adenocarcinoma.
Wang J; Yu XF; OUYang N; Luo QL; Zhao SY; Guan XF; Chen T; Li JX
J Toxicol Environ Health A; 2019; 82(1):37-45. PubMed ID: 30626254
[TBL] [Abstract][Full Text] [Related]
39. A prognostic predictor panel with DNA methylation biomarkers for early-stage lung adenocarcinoma in Asian and Caucasian populations.
Kuo IY; Jen J; Hsu LH; Hsu HS; Lai WW; Wang YC
J Biomed Sci; 2016 Aug; 23(1):58. PubMed ID: 27484806
[TBL] [Abstract][Full Text] [Related]
40. A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
Sandoval J; Mendez-Gonzalez J; Nadal E; Chen G; Carmona FJ; Sayols S; Moran S; Heyn H; Vizoso M; Gomez A; Sanchez-Cespedes M; Assenov Y; Müller F; Bock C; Taron M; Mora J; Muscarella LA; Liloglou T; Davies M; Pollan M; Pajares MJ; Torre W; Montuenga LM; Brambilla E; Field JK; Roz L; Lo Iacono M; Scagliotti GV; Rosell R; Beer DG; Esteller M
J Clin Oncol; 2013 Nov; 31(32):4140-7. PubMed ID: 24081945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
